A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Clinical trial NCT02322814 · TERMINATED

Trial details

NCT number

NCT02322814

Sponsor

Hoffmann-La Roche

Status

TERMINATED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2015-03-12

Primary completion

2018-08-10

Enrollment

169

View on ClinicalTrials.gov